CRMD (Pharmaceuticals) Stock Valuation & Fair Value Trading above fair value
CRMD (Pharmaceuticals) trades at a blended P/E of 6.7, about 17% above its historical normal valuation, with a forward growth estimate of -31.4% and a PEG of —. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- Negative growth forecast
Frequently asked questions
Is CRMD overvalued?
At a blended P/E of 6.7 versus its historical normal P/E of 5.7, CRMD trades about 17% above its typical valuation. tickerseer currently rates it trading above fair value.
What is CRMD's fair value and PEG?
CRMD trades at a blended P/E of 6.7 against a historical normal P/E of 5.7, and a forward growth estimate of -31.4%.
Has tickerseer's rating of CRMD changed?
tickerseer's rating has been trading above fair value since 2026-08-07.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.